Physician profile
Alan Kauppi
NPI 1093799322
$2,783.68
in general payments reported to CMS, 2019-2025
25 companies · $384 in 2025
The $384 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $498 · 2020: $53.08 · 2021: $123 · 2022: $1,192 · 2023: $420 · 2024: $114 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $882 · Education: $36.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $881.98 |
| Education | $36.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $314.57 | 2019-2025 | Wegovy, Sogroya, Ozempic |
| Dexcom, INC. | $292.70 | 2021-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $241.24 | 2019-2023 | Mounjaro, Jardiance, Lyumjev |
| Tandem Diabetes Care, INC. | $215.84 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $208.69 | 2019-2025 | Freestyle Libre 3 |
| Mannkind Corporation | $190.69 | 2022-2023 | Afrezza |
| Insulet Corporation | $123.20 | 2019-2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.37 | 2019 | |
| Medtronic Minimed, INC. | $114.04 | 2019 | |
| Amgen INC. | $113.65 | 2024 | Tepezza |
| Horizon Therapeutics Plc | $112.96 | 2022-2023 | Tepezza |
| Xeris Pharmaceuticals, INC. | $79.97 | 2022-2023 | Gvoke Hypopen |
| Recordati_rare_diseases_inc. | $73.06 | 2022 | |
| Eusa Pharma (US) LLC | $73.06 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $63.37 | 2022-2023 | Imcivree |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Embecta Corp. | $61.30 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Bayer Healthcare Pharmaceuticals INC. | $56.01 | 2022 | |
| Corcept Therapeutics | $50.27 | 2022-2023 | Korlym |
| Janssen Pharmaceuticals, INC | $46.25 | 2019 | |
| Grt US Holding, INC. | $45.99 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $45.85 | 2022-2023 | Farxiga |
| Ultragenyx Pharmaceutical INC. | $44.78 | 2022 | |
| Antares Pharma, INC. | $42.83 | 2022 | |
| Medtronic, INC. | $42.48 | 2022 | |
| Glaxosmithkline, LLC. | $12.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Kauppi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.